New Oriental offers a cash-rich Chinese education franchise with growing learning demand, improving shareholder returns, and an attractive valuation, although regulatory uncertainty and East Buy's lower-margin expansion could constrain profitability.
Carvana's integrated online vehicle-retail platform can compound earnings through sustained market-share gains and operating scale, but demanding valuation multiples and financing-sensitive margins limit the margin of safety.
American Electric Power offers durable regulated utility earnings and accelerated growth from electricity infrastructure demand, but elevated historical valuation and the funding burden of its $100B capital program constrain near-term upside.
Viking Therapeutics could establish a valuable obesity-drug franchise through injectable and oral VK2735, but its lack of revenue, substantial cash burn, and dependence on successful Phase 3 trials create significant investment risk.
GE Vernova can compound earnings through a historic expansion in power generation and grid investment, supported by a massive backlog and stronger margins, although elevated valuation expectations and project execution risks limit its margin of safety.
TransMedics is building a differentiated organ preservation and transplant logistics platform with significant long-term growth potential, but slowing revenue growth, margin compression, and capital-intensive expansion weaken its near-term investment appeal.
Establishment Labs can compound revenue through U.S. Motiva adoption and minimally invasive innovation, but its premium valuation, substantial debt, and unproven cash-flow durability limit the margin of safety.
Wix combines a sticky subscription software franchise with AI-driven growth potential and attractive cash-flow valuation, but Base44 execution risk, declining FCF margins, and increased leverage constrain near-term conviction.
Arcutis offers sustained dermatology-drug growth and expanding profitability through ZORYVE, but dependence on one franchise, reimbursement pressure, dilution, and a premium valuation limit the margin of safety.
Adaptive Biotechnologies benefits from expanding MRD testing adoption and improving operating leverage, but its demanding sales valuation, persistent losses, and separation uncertainty limit near-term investment appeal.
St. Joe's scarce Northwest Florida landholdings and expanding hospitality operations support long-term value creation, but premium earnings multiples and geographically concentrated real estate risks constrain near-term upside.
Mirion benefits from long-term nuclear safety and radiation technology demand, supported by accelerating orders and cash generation, but acquisition-related dilution, leverage, and a demanding earnings multiple limit near-term upside.